TW202311290A - 用於治療或預防炎症性疾病之抗人類pd-1促效劑抗體及含有其之醫藥組合物 - Google Patents

用於治療或預防炎症性疾病之抗人類pd-1促效劑抗體及含有其之醫藥組合物 Download PDF

Info

Publication number
TW202311290A
TW202311290A TW111118052A TW111118052A TW202311290A TW 202311290 A TW202311290 A TW 202311290A TW 111118052 A TW111118052 A TW 111118052A TW 111118052 A TW111118052 A TW 111118052A TW 202311290 A TW202311290 A TW 202311290A
Authority
TW
Taiwan
Prior art keywords
antibody
amino acid
human
acid sequence
seq
Prior art date
Application number
TW111118052A
Other languages
English (en)
Chinese (zh)
Inventor
本庶佑
太田明夫
但馬正樹
鎌田春彦
永田諭志
鈴木健介
福島崇恵
徳丸陽介
Original Assignee
公益財團法人神戸醫療産業都市推進機構
國立研究開發法人醫藥基盤・健康・營養研究所
日商明治制果藥業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 公益財團法人神戸醫療産業都市推進機構, 國立研究開發法人醫藥基盤・健康・營養研究所, 日商明治制果藥業股份有限公司 filed Critical 公益財團法人神戸醫療産業都市推進機構
Publication of TW202311290A publication Critical patent/TW202311290A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW111118052A 2021-05-13 2022-05-13 用於治療或預防炎症性疾病之抗人類pd-1促效劑抗體及含有其之醫藥組合物 TW202311290A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2021081913 2021-05-13
JP2021-081913 2021-05-13
JP2021-086534 2021-05-21
JP2021086534 2021-05-21

Publications (1)

Publication Number Publication Date
TW202311290A true TW202311290A (zh) 2023-03-16

Family

ID=84029692

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111118052A TW202311290A (zh) 2021-05-13 2022-05-13 用於治療或預防炎症性疾病之抗人類pd-1促效劑抗體及含有其之醫藥組合物

Country Status (13)

Country Link
US (1) US20240317859A1 (https=)
EP (1) EP4339289A4 (https=)
JP (1) JPWO2022239820A1 (https=)
KR (1) KR20240007203A (https=)
AR (1) AR125887A1 (https=)
AU (1) AU2022272835A1 (https=)
BR (1) BR112023023400A2 (https=)
CA (1) CA3217199A1 (https=)
IL (1) IL307887A (https=)
MX (1) MX2023013207A (https=)
TW (1) TW202311290A (https=)
UY (1) UY39768A (https=)
WO (1) WO2022239820A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230183347A1 (en) * 2020-05-25 2023-06-15 Foundation For Biomedical Research And Innovation At Kobe PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease
KR20250122541A (ko) 2022-10-25 2025-08-13 사이즈믹 테라퓨틱, 인코포레이티드. 변이체 IgG FC 폴리펩티드 및 그 용도
CN117024595B (zh) * 2023-10-08 2024-01-26 江西乐成欣生生物技术研究有限责任公司 抗人st2的单克隆抗体及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
AU2009290544B2 (en) * 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
ES2893855T3 (es) * 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
DK3237446T3 (en) * 2014-12-22 2021-07-26 Pd 1 Acquisition Group Llc Anti-PD-1-antistoffer
BR112018006237A2 (pt) 2015-09-29 2018-10-09 Celgene Corp proteínas de ligação a pd-1 e métodos de uso das mesmas
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
TWI890481B (zh) 2018-02-09 2025-07-11 日商小野藥品工業股份有限公司 雙特異性抗體
AR114127A1 (es) * 2018-03-02 2020-07-22 Lilly Co Eli Anticuerpos agonistas contra pd-1 y usos de estos
KR20210010896A (ko) 2018-05-14 2021-01-28 이뮤노코어 리미티드 이기능성 결합 폴리펩타이드
KR20250126805A (ko) 2019-06-05 2025-08-25 아납티스바이오, 아이엔씨. Pd-1 작용제 및 이의 사용 방법
JP7185614B2 (ja) 2019-11-18 2022-12-07 株式会社エクスモーション 情報処理装置、及び情報処理プログラム
JP7310572B2 (ja) 2019-11-29 2023-07-19 日本電気株式会社 計数装置、制御方法、及びプログラム
US20230183347A1 (en) * 2020-05-25 2023-06-15 Foundation For Biomedical Research And Innovation At Kobe PD-1 Agonist-Containing Pharmaceutical Composition for Treating or PReventing TH2-Mediated Disease

Also Published As

Publication number Publication date
US20240317859A1 (en) 2024-09-26
MX2023013207A (es) 2023-11-15
EP4339289A4 (en) 2025-10-08
IL307887A (en) 2023-12-01
AU2022272835A9 (en) 2023-11-16
AR125887A1 (es) 2023-08-23
AU2022272835A1 (en) 2023-11-02
KR20240007203A (ko) 2024-01-16
WO2022239820A1 (ja) 2022-11-17
CA3217199A1 (en) 2022-11-17
BR112023023400A2 (pt) 2024-01-23
EP4339289A1 (en) 2024-03-20
UY39768A (es) 2022-11-30
JPWO2022239820A1 (https=) 2022-11-17

Similar Documents

Publication Publication Date Title
JP7273904B2 (ja) 液性免疫応答の増強方法
US11660340B2 (en) Combination therapy using T cell redirection antigen binding molecule against cell having immunosuppressing function
JP7287963B2 (ja) 抗ｔｉｇｉｔ抗体並びに治療剤及び診断剤としてのその使用
US11505605B2 (en) T cell-redirected antigen-binding molecule for cells having immunosuppression function
KR101834708B1 (ko) 암의 치료에 이용하기 위한 세포상해 유도 치료제
US11639393B2 (en) Anti-CCR8 antibodies
TW201920275A (zh) 藉由細胞表現之調控生物活性的抗體
TW202311290A (zh) 用於治療或預防炎症性疾病之抗人類pd-1促效劑抗體及含有其之醫藥組合物
TW201920657A (zh) 藉由細胞表現之調控生物活性的抗體
US20240103010A1 (en) Pvrl2 and/or pvrig as biomarkers for treatment
US20230400467A1 (en) Pvrl2 and/or pvrig as biomarkers for treatment
CN117203341A (zh) 用于治疗或预防炎症性疾病的抗人pd-1激动剂抗体和含有其的药物组合物
HK40106942A (en) Anti-human pd-1 agonist antibody for treating or preventing inflammatory diseases, and pharmaceutical composition containing same
WO2025016450A1 (en) Combination of cldn18.2 and gucy2c targeted antagonist therapy
TW202611084A (zh) 抗ccr8抗體
TW201927336A (zh) 細胞毒性ｔ細胞耗竭用組成物